Physician profile
Charles C Gregory
NPI 1477581221
$1,833.09
in general payments reported to CMS, 2019-2025
24 companies · $85.17 in 2025
The $85.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $347 · 2021: $339 · 2022: $430 · 2023: $245 · 2024: $16.51 · 2025: $85.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $423.49 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $307.61 | 2019-2024 | Breztri |
| Novo Nordisk INC | $296.30 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $140.61 | 2019 | |
| Abbvie INC. | $69.16 | 2021-2025 | |
| Abbott Laboratories | $68.82 | 2022-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $59.03 | 2019-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.67 | 2019-2020 | |
| Eisai INC. | $50.44 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.75 | 2019-2021 | |
| Pfizer INC. | $44.87 | 2020-2022 | |
| Lilly USA, LLC | $44.36 | 2021-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $44.16 | 2020-2023 | Trintellix |
| Exact Sciences Corporation | $39.24 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $27.10 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $20.34 | 2020 | |
| Glaxosmithkline, LLC. | $13.97 | 2022 | |
| Aytu Biopharma, INC. | $13.67 | 2020 | |
| Adlon Therapeutics L.P. | $12.90 | 2021 | |
| Esperion Therapeutics, INC. | $11.84 | 2021 | |
| Amgen INC. | $11.59 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.34 | 2019 | |
| Shire North American Group INC | $11.11 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.72 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.